Shulman DeMeo Asset Management LLC Has $1.41 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Shulman DeMeo Asset Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 2.3% during the third quarter, HoldingsChannel.com reports. The fund owned 8,700 shares of the company’s stock after selling 202 shares during the period. Johnson & Johnson makes up approximately 0.3% of Shulman DeMeo Asset Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Shulman DeMeo Asset Management LLC’s holdings in Johnson & Johnson were worth $1,410,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. RDA Financial Network raised its holdings in Johnson & Johnson by 1.6% during the 3rd quarter. RDA Financial Network now owns 6,039 shares of the company’s stock worth $979,000 after buying an additional 93 shares during the period. Swedbank AB grew its stake in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after acquiring an additional 111,570 shares in the last quarter. Zhang Financial LLC grew its stake in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Zhang Financial LLC now owns 10,640 shares of the company’s stock worth $1,724,000 after acquiring an additional 159 shares in the last quarter. Mustard Seed Financial LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $297,000. Finally, Ulland Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 11.1% during the 3rd quarter. Ulland Investment Advisors LLC now owns 1,506 shares of the company’s stock worth $244,000 after acquiring an additional 150 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Morgan Stanley raised their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. TD Securities decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Thursday, October 10th. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.31.

Johnson & Johnson Stock Performance

JNJ traded up $2.50 during trading on Tuesday, hitting $164.10. The stock had a trading volume of 10,213,406 shares, compared to its average volume of 7,050,074. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a 50 day moving average price of $162.60 and a 200-day moving average price of $154.48. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The firm has a market cap of $394.94 billion, a price-to-earnings ratio of 10.07, a P/E/G ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. Johnson & Johnson’s payout ratio is 30.92%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.